ENTA News and Press, Enanta Pharmaceuticals Inc. From 08/31/20

Fortress Biotech reports positive data from CUTX-101 Fortress Biotech Inc. ( FBIO ) reported positive topline clinical efficacy data for CUTX-101. The trial is being conducted by its partner company Cyprium Therapeutics. The data showed the drug candidate brought about statistically sign...

Data from Enanta Pharmaceuticals' (NASDAQ: ENTA ) development programs for non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) will be virtually  presented at the European Association for the Study of the Liver Annual Meeting. More news on: Enanta Pharmaceuticals, Inc....

New Pharmacokinetic and Safety Results from Phase 1a Study of HBV Core Inhibitor EDP-514, Highlighting Good Safety and Tolerability, and Pharmacokinetics Suitable for Once Daily Dosing Phase 2a ARGON-1 Study for FXR Agonist EDP-305 Targeting NASH, Showing Significant Alanine Transa...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that clinical data from Enanta’s wholly-owned development programs for non-alcoholic steatohepatitis (N...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with their 2020 Q3 earnings Read more ...

Image source: The Motley Fool. Enanta Pharmaceuticals Inc   (NASDAQ: ENTA) Q3 2020 Earnings Call Aug 4, 2020 , 4:30 p.m. ET Operator Continue reading

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2020 Earnings Conference Call August 04, 2020, 16:30 ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration and CF...

Enanta Pharma (NASDAQ: ENTA ) : Q3 GAAP EPS of -$0.71 beats by $0.26 . More news on: Enanta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Initiated Phase 1b Study of EDP-514 in Viremic HBV Patients and Resumed Phase 1b Study of EDP-514 in NUC-Suppressed HBV Patients; Preliminary Data Expected in 1H 2021 and 2Q 2021, Respectively Plans to Initiate Two Phase 2 Studies of EDP-938 in Pediatric and Adult Transplant Patient...